453 related articles for article (PubMed ID: 33801192)
1. Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.
Mirabelli M; Chiefari E; Tocci V; Caroleo P; Giuliano S; Greco E; Luque RM; Puccio L; Foti DP; Aversa A; Brunetti A
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801192
[TBL] [Abstract][Full Text] [Related]
2. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
[TBL] [Abstract][Full Text] [Related]
4. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin.
Witkowski M; Wilkinson L; Webb N; Weids A; Glah D; Vrazic H
Diabetes Ther; 2018 Jun; 9(3):1233-1251. PubMed ID: 29713961
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data.
Divino V; Boye KS; Lebrec J; DeKoven M; Norrbacka K
Diabetes Ther; 2019 Jun; 10(3):1067-1088. PubMed ID: 31028689
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis.
Patel H; Munir K; Sutherland S; Karanikas CA; Konig M
Diabetes Ther; 2019 Dec; 10(6):2321-2330. PubMed ID: 31605302
[TBL] [Abstract][Full Text] [Related]
8. Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study.
Federici MO; McQuillan J; Biricolti G; Losi S; Lebrec J; Richards C; Miglio C; Norrbacka K
Diabetes Ther; 2018 Apr; 9(2):789-801. PubMed ID: 29525885
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs.
Witkowski M; Wilkinson L; Webb N; Weids A; Glah D; Vrazic H
Diabetes Ther; 2018 Jun; 9(3):1149-1167. PubMed ID: 29675798
[TBL] [Abstract][Full Text] [Related]
10. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
Gæde P; Johansen P; Tikkanen CK; Pollock RF; Hunt B; Malkin SJP
Diabetes Ther; 2019 Aug; 10(4):1297-1317. PubMed ID: 31098942
[TBL] [Abstract][Full Text] [Related]
11. Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment.
Jabbour S; Paik JS; Aleppo G; Sharma P; Gomez Valderas E; Benneyworth BD
Endocr Pract; 2024 May; ():. PubMed ID: 38723893
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors.
Ma J; Zhang B; Hou J; Peng Y
Diabetes Ther; 2021 Jan; 12(1):211-222. PubMed ID: 33161492
[TBL] [Abstract][Full Text] [Related]
13. EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM.
Davidson JA; Manghi FP; Yu M; Linetzky B; Landó LF
Endocr Pract; 2016 Dec; 22(12):1406-1414. PubMed ID: 27540883
[TBL] [Abstract][Full Text] [Related]
14. Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus.
Lee J; Kim R; Kim MH; Lee SH; Cho JH; Lee JM; Jang SA; Kim HS
Prim Care Diabetes; 2023 Oct; 17(5):460-465. PubMed ID: 37541792
[TBL] [Abstract][Full Text] [Related]
15. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study.
Ghosal S; Sinha B
Clin Diabetes Endocrinol; 2018; 4():11. PubMed ID: 29760945
[TBL] [Abstract][Full Text] [Related]
17. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
García-Pérez LE; Boye KS; Rosilio M; Jung H; Heitmann E; Norrbacka K; Federici MO; Gentilella R; Guerci B; Giorgino F; Aigner U; Sapin H
Diabetes Ther; 2021 Jul; 12(7):1929-1946. PubMed ID: 34097244
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
19. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
[TBL] [Abstract][Full Text] [Related]
20. Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.
Jain AB; Kanters S; Khurana R; Kissock J; Severin N; Stafford SG
Diabetes Ther; 2021 Feb; 12(2):527-536. PubMed ID: 33367981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]